BeStock  
Stocks › HALO

Halozyme Therapeutics HALO

US equityMarket cap rank #776
$108.92 −$1.49 (-1.35%)
Market open · Oct 1, 3:30 pm ET · After hours $110.00 -0.36%
Open$109.93
Prev close$110.40
Day range$107.86 – $110.49
Volume1.48M
Market cap$12.36B
P/E (TTM)31.9
Dividend yield–

HALO Stock News

Headlines matching Halozyme Therapeutics or the HALO ticker, most recent first.

  • Analysts' Top NA Picks: High Roller Technologies, Inc. (ROLR), Halozyme (HALO)TipRanks · 3 Sep 2026
  • H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $115Market news · 3 Sep 2026
  • Form 144 | Halozyme Therapeutics(HALO.US) Director Proposes to Sell 3.64 Million in Common StocksMarket news · 17 Sep 2026
  • Halozyme Therapeutics(HALO.US) Officer Sells US$6.44 Million in Common StockMarket news · 12 Sep 2026
  • A Quick Look at Today's Ratings for Halozyme Therapeutics(HALO.US), With a Forecast Between $93 to $115Market news · 8 Aug 2026
  • Halozyme Therapeutics(HALO.US) Officer Sells US$6.28 Million in Common StockMarket news · 20 Aug 2026
  • RIMBACO: JOINT ANNOUNCEMENT1. CLOSE OF MANDATORY UNCONDITIONAL CASH OFFER BY CMB INTERNATIONAL CAPITAL LIMITED AND CEB INTERNATIONAL CAPITAL CORPORATION LIMITED FOR AND ON BEHALF OF AUREOLE HALO LIMITED TO ACQUIRE ALL THE ISSUED SHARES OF RIMBACO GROUP GLOBAL LIMITHKEX · 7 Jul 2026
  • H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $95Market news · 22 Jul 2026
  • Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Maintains Target Price $75Market news · 15 Jun 2026
  • Goldman Sachs Maintains Halozyme Therapeutics(HALO.US) With Sell Rating, Raises Target Price to $57Market news · 15 Jun 2026
  • Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $93Market news · 15 Jun 2026
  • J.P. Morgan Sticks to Its Hold Rating for Halozyme (HALO)TipRanks · 20 May 2026
  • China Resources Land Life (1209.HK): A leading operator of consumer‑focused HALO assets in China.Huatai Securities · 15 May 2026
  • TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $96Market news · 12 May 2026
  • Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Cuts Target Price to $66.41Market news · 12 May 2026

Discussion

No comments yet — be the first to weigh in on HALO.

Leave a comment

Scroll to Top